What happened Shares of Oxford Immunotec Global (NASDAQ: OXFD) were skyrocketing 27.1% as of 12:05 p.m. EST on Thursday. The big jump came after PerkinElmer (NYSE: PKI) announced plans to acquire Oxford Immunotec for $591 million. So what PerkinElmer offered $22 per share to buy Oxford, a 28% premium to the closing price of the healthcare stock on Jan. 5, and a 53.5% premium to Oxford's volume-weighted average price over the 90 days leading up to that date. Image source: Getty Images. This is obviously a big win for Oxford Immunotec shareholders. But what about for PerkinElmer? The big healthcare company will pick up Oxford's tuberculosis tests, which fits in well with PerkinElmer's lineup of infectious-disease testing solutions. The deal won't make a big splash with PerkinElmer's financial performance right out of the gate, though. The company expects that its acquisition of Oxford Immunotec will be "modestly accretive" to adjusted earnings in the first year after the transaction closes. But PerkinElmer thinks that the sales growth from Oxford's products will be greater than for its own diagnostics products. Now what There are still a few hoops to jump through for the acquisition to close. While both boards of directors have approved the buyout, the shareholders of Oxford Immunotec must also give their approval. In addition, PerkinElmer will need to obtain U.K. court approval. Assuming there are no roadblocks, the transaction should close in the first half of this year. 10 stocks we like better than Oxford Immunotec GlobalWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Oxford Immunotec Global wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of November 20, 2020 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.Source